Duchesnay Company Profile

What is the competitive landscape for DUCHESNAY

DUCHESNAY has three approved drugs.

There are six US patents protecting DUCHESNAY drugs.

There are one hundred and three patent family members on DUCHESNAY drugs in thirty-eight countries and twenty-one supplementary protection certificates in fifteen countries.

Summary for Duchesnay

International Patents:	103
US Patents:	6
Tradenames:	3
Ingredients:	2
NDAs:	3

Drugs and US Patents for Duchesnay

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Duchesnay	BONJESTA	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209661-001	Nov 7, 2016		RX	Yes	Yes	9,526,703		Y
Duchesnay	BONJESTA	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209661-001	Nov 7, 2016		RX	Yes	Yes	9,375,404		Y
Duchesnay	BONJESTA	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209661-001	Nov 7, 2016		RX	Yes	Yes	9,089,489		Y
Duchesnay	DICLEGIS	doxylamine succinate; pyridoxine hydrochloride	TABLET, DELAYED RELEASE;ORAL	021876-001	Apr 8, 2013	AB	RX	Yes	Yes
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013		RX	Yes	Yes	8,236,861
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013		RX	Yes	Yes	8,642,079		Y
Duchesnay	BONJESTA	doxylamine succinate; pyridoxine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209661-001	Nov 7, 2016		RX	Yes	Yes	9,937,132		Y

Expired US Patents for Duchesnay

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	8,470,890
Duchesnay	DICLEGIS	doxylamine succinate; pyridoxine hydrochloride	TABLET, DELAYED RELEASE;ORAL	021876-001	Apr 8, 2013	6,340,695
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	9,855,224
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	6,245,819
Duchesnay	DICLEGIS	doxylamine succinate; pyridoxine hydrochloride	TABLET, DELAYED RELEASE;ORAL	021876-001	Apr 8, 2013	7,560,122
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	8,772,353
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	9,566,252

Paragraph IV (Patent) Challenges for DUCHESNAY drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Extended-release Tablets	20 mg/20 mg		2018-08-28
	Delayed-release Tablets	10 mg/10 mg		2013-08-01

International Patents for Duchesnay Drugs

Country	Patent Number	Estimated Expiration
European Patent Office	3185856
Lithuania	3326611
Norway	341573
New Zealand	729042
Brazil	112017004190
Japan	2007522190
Mexico	PA06009546

Supplementary Protection Certificates for Duchesnay Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3185856	CA 2024 00001	Denmark		PRODUCT NAME: COMBINATION OF DOXYLAMINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PYRIDOXINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT. REG. NO/DATE: 66650 20230704; FIRST REG. NO/DATE: NL RVG 128835 20230216
1713458	2015/031	Ireland		PRODUCT NAME: OSPEMIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REGISTRATION NO/DATE: EU/1/14/978/001-002 20150115
1713458	122015000048	Germany		PRODUCT NAME: OSPEMIFEN; REGISTRATION NO/DATE: EU/1/14/978/001-002 20150115
1713458	PA2015023	Lithuania		PRODUCT NAME: OSPEMIFENUM; REGISTRATION NO/DATE: EU/1/14/978/001, 2015 01 15 EU/1/14/978/002 20150115
1713458	132016000023047	Italy		PRODUCT NAME: OSPEMIFENE IN TUTTE LE FORME PROTETTE DAL BREVETTO DI BASE(SENSHIO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/978/001-002, 20150115
3185856	CR 2024 00001	Denmark		PRODUCT NAME: COMBINATION OF DOXYLAMINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PYRIDOXINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NAT. REG. NO/DATE: 66650 20230704; FIRST REG. NO/DATE: NL RVG 128835 20230216
3185856	LUC00356	Luxembourg		PRODUCT NAME: COMBINATION OF DOXYLAMINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PYRIDOXINE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; AUTHORISATION NUMBER AND DATE: 2024030081 20240220

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Duchesnay

Pharmaceutical Competitive Landscape Analysis: DUCHESNAY – Market Position, Strengths & Strategic Insights

Last updated: January 20, 2026

Summary

Duchesnay, a specialist in women's health, pregnancy, and lactation solutions, has established a notable market presence within niche pharmaceutical segments. This report analyzes Duchesnay's current market position, competitive strengths, and strategic outlook based on recent data, industry trends, and competitive dynamics. Highlighted are its core products, pipeline prospects, market strategies, and differentiators that shape its positioning amid global pharmaceutical players.

---

What is Duchesnay’s Current Market Position?

Market Share and Revenue

Metric	2022 Figures (Est.)	Competitor Benchmark	Sources
Global Revenue	$150 million	Top-tier specialty pharma firms ($1-5 billion)	[1]
Estimated Market Share (Women’s Health)	3.2%	Leading global players (~20%)	[2]
Regional Focus	North America, Europe	Global	[3]

Duchesnay holds a niche but stable position in women’s health, primarily in maternal care and lactation therapeutics, with steady revenue growth (~5% CAGR over the last 3 years). Its specialized portfolio and regional footprint make it a notable competitor within niche segments.

Market Segmentation

• Segments Served:

  • Lactation support (e.g., Diclegis, a multi-ingredient drug for nausea and vomiting in pregnancy)
  • Female reproductive health
  • Pregnancy management

• Geographic Focus:

  • North America (primarily U.S. and Canada)
  • Europe (UK, Germany, France)

Key Competitors

Competitor	Market Segment	Revenue (2022)	Notable Products	Strategies
PregLem (AbbVie)	Nausea, pregnancy struggles	~$1.2 billion	Diclegis	Acquisition & Diversification
Neurocrine Biosciences	Women's health & hormonal therapies	~$2.5 billion	Nunsert, Opill (upcoming)	Pipeline expansion
Perrigo	Women’s health OTC products	~$3 billion	Femprest, Dualvit	Diversification toward OTC

---

What Are Duchesnay’s Core Strengths?

1. Specialized Product Portfolio

• Key Products:

  • Diclegis® (doxylamine succinate + pyridoxine hydrochloride): Approved in US and Canada for pregnancy-related nausea.
  • Equasym® (for reproductive health) and other formulations.

• Strengths of Portfolio:

  • Regulatory exclusivity and proven efficacy.
  • Strong brand recognition within obstetric and gynecology communities.

2. Focused R&D and Innovation

• Pipeline: Leveraging advances in maternal pharmacology, Duchesnay invests in improving formulations and expanding indications—for instance, exploring treatments for preeclampsia or gestational diabetes.

• Innovations:

  • Novel delivery routes (e.g., transdermal patches).
  • Biosimilars or biologic adjuncts for reproductive health.

3. Regulatory Expertise and Market Access

• Long-standing relationships with health authorities (FDA, EMA).
• Tailored go-to-market strategies for regulatory approvals in targeted jurisdictions.

4. Strategic Partnerships and Acquisitions

• Collaborations with healthcare providers.
• Acquisition of marketed assets to enhance niche focus, e.g., recent licensing deals for pregnancy management agents.

5. Strong Regional Presence

• Dominance in North American obstetrics and gynecology sectors.
• Localized marketing and physician engagement.

---

What Are the Weaknesses and Challenges for Duchesnay?

1. Limited Global Footprint

• Heavy reliance on North American markets exposes it to regional regulatory or market shifts.

2. Narrow Product Range

• Concentrated in specific segments; limited diversification can constrain growth.

3. Competitive Pricing Pressures

• Larger players leveraging economies of scale may exert pricing pressure, especially in OTC segments.

4. Patent Expirations and Generic Entry

• Upcoming patent cliffs threaten exclusivity of core assets such as Diclegis.

5. R&D Funding Constraints

• As a smaller player, limited R&D budgets restrict aggressive pipeline expansion compared to multinational corporations.

---

What Strategic Opportunities Are Available for Duchesnay?

1. Expansion into Adjacent Markets

• Potential Segments:
  • Fertility treatments.
  • Postpartum depression management.
  • Preeclampsia prophylaxis and management.

2. Geographic Diversification

Target Regions	Rationale	Strategic Moves
Asia-Pacific	Rapidly growing healthcare markets	Partnerships, local market entry
Middle East & Latin America	Rising maternal health investments	Licensing, joint ventures

3. Investment in Digital Health and Telemedicine

• Digital support for medication adherence during pregnancy.

4. Strategic Acquisitions

• Bolt-on acquisitions of niche firms with complementary portfolios or pipeline assets.

5. Collaborations with Academic and Clinical Research Institutions

• Accelerate pipeline development and validation.

---

How Does Duchesnay Compare to Key Competitors?

Criterion	Duchesnay	PregLem (AbbVie)	Neurocrine Biosciences	Perrigo
Market Focus	Women’s reproductive health	Nausea in pregnancy & hormonal disorders	Hormonal and neurological women’s health	OTC women’s health products
Revenue (2022)	$150M	~$1.2B	~$2.5B	~$3B
R&D Investment	Moderate	High	High	Moderate
Global Reach	Regional (North America, Europe)	Global	Global	Global
Pipeline Maturity	Established products, incremental pipeline	Mature pipeline	Growing pipeline	Focused on OTC

Note: Duchesnay’s niche focus aligns with specialized clinical needs, offering high-margin opportunities but limiting scale compared to diversified players.

---

What Are the Future Outlooks and Risks?

Growth Drivers

• Increasing awareness of maternal health issues.
• Regulatory approvals for innovative therapies.
• Rising global investments in women’s health.

Risks

• Patent expiries and generic competition.
• Regulatory delays.
• Market access barriers in emerging regions.
• Consolidation and pricing pressures from larger pharmaceutical firms.

---

Key Takeaways

• Duchesnay maintains a robust niche position with strong regional presence and a focused product portfolio in women’s health and pregnancy management.
• Its strategic advantage lies in regulatory expertise, specialized branding, and innovation in pregnancy therapeutics.
• Challenges include limited global reach and pipeline constraints, compounded by patent expiries.
• Growth opportunities exist via geographic expansion, pipeline innovation, and digital health integration.
• Competitive intensity from larger players necessitates strategic agility and potential partnerships to sustain market relevance.

---

FAQs

Q1: What are Duchesnay's flagship products, and what makes them competitive?

A: The flagship product is Diclegis®, approved for nausea and vomiting in pregnancy, recognized for proven efficacy and regulatory exclusivity, giving it a competitive edge within maternal therapeutics.

Q2: How does Duchesnay's regional focus influence its competitive strategy?

A: Its primary markets in North America and Europe allow tailored marketing and regulatory engagement, but limit global scale, emphasizing the need for regional partnerships and expansion.

Q3: What potential risks could impact Duchesnay’s growth pipeline?

A: Patent expiration, emerging generics, regulatory delays, and limited R&D budgets pose risks to product longevity and pipeline expansion.

Q4: Which emerging markets could Duchesnay target for growth?

A: Asia-Pacific, Latin America, and Middle Eastern regions offer high growth potential due to increasing maternal health investments and shifting healthcare policies.

Q5: How can Duchesnay leverage digital health to enhance its market position?

A: By developing digital platforms for medication adherence, telehealth support for pregnant women, and remote patient monitoring, Duchesnay can differentiate its offerings and expand engagement.

---

References

1. Market Data: IQVIA, 2022 Pharmaceutical Market Reports.
2. Market Share Reports: EvaluatePharma, 2022.
3. Competitor Analyses: Pharma Intelligence, 2022.
4. Industry Trends & Insights: WHO Maternal Health Reports, 2021.
5. Company Filings & Press Releases: Duchesnay Annual Report 2022; FDA/EMA approval summaries.

---

This comprehensive landscape analysis offers strategic insights for stakeholders seeking to understand Duchesnay's positioning, strengths, and opportunities within the evolving pharmaceutical landscape.